These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12822182)

  • 1. Synthesis of 2-(4-biphenylyl)quinoline-4-carboxylate and carboxamide analogs. New human neurokinin-3 (hNK-3) receptor antagonists.
    Saudi MN; Rostom SA; Fahmy HT; El Ashmawy IM
    Arch Pharm (Weinheim); 2003 Jun; 336(3):165-74. PubMed ID: 12822182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
    Giardina GA; Raveglia LF; Grugni M; Sarau HM; Farina C; Medhurst AD; Graziani D; Schmidt DB; Rigolio R; Luttmann M; Cavagnera S; Foley JJ; Vecchietti V; Hay DW
    J Med Chem; 1999 Mar; 42(6):1053-65. PubMed ID: 10090788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of carboxyflavones as structurally rigid CysLT1 (LTD4) receptor antagonists.
    Zwaagstra ME; Timmerman H; van de Stolpe AC; de Kanter FJ; Tamura M; Wada Y; Zhang MQ
    J Med Chem; 1998 Apr; 41(9):1428-38. PubMed ID: 9554876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity and selectivity in quinoline tachykinin receptor antagonists.
    Blaney FE; Raveglia LF; Artico M; Cavagnera S; Dartois C; Farina C; Grugni M; Gagliardi S; Luttmann MA; Martinelli M; Nadler GM; Parini C; Petrillo P; Sarau HM; Scheideler MA; Hay DW; Giardina GA
    J Med Chem; 2001 May; 44(11):1675-89. PubMed ID: 11356103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
    Sarau HM; Griswold DE; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Webb EF; Martin LD; Legos JJ; Whitmore RG; Barone FC; Medhurst AD; Luttmann MA; Giardina GA; Hay DW
    J Pharmacol Exp Ther; 2000 Oct; 295(1):373-81. PubMed ID: 10992004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 1. Identification of the 4-quinolinecarboxamide framework.
    Giardina GA; Sarau HM; Farina C; Medhurst AD; Grugni M; Raveglia LF; Schmidt DB; Rigolio R; Luttmann M; Vecchietti V; Hay DW
    J Med Chem; 1997 Jun; 40(12):1794-807. PubMed ID: 9191956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.
    Hay DW; Giardina GA; Griswold DE; Underwood DC; Kotzer CJ; Bush B; Potts W; Sandhu P; Lundberg D; Foley JJ; Schmidt DB; Martin LD; Kilian D; Legos JJ; Barone FC; Luttmann MA; Grugni M; Raveglia LF; Sarau HM
    J Pharmacol Exp Ther; 2002 Jan; 300(1):314-23. PubMed ID: 11752131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of carboxylated chalcones: a novel series of CysLT1 (LTD4) receptor antagonists.
    Zwaagstra ME; Timmerman H; Tamura M; Tohma T; Wada Y; Onogi K; Zhang MQ
    J Med Chem; 1997 Mar; 40(7):1075-89. PubMed ID: 9089329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of the first non-peptide full agonists for the human bradykinin B(2) receptor incorporating 4-(2-picolyloxy)quinoline and 1-(2-picolyl)benzimidazole frameworks.
    Sawada Y; Kayakiri H; Abe Y; Mizutani T; Inamura N; Asano M; Hatori C; Aramori I; Oku T; Tanaka H
    J Med Chem; 2004 May; 47(11):2853-63. PubMed ID: 15139763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and 5-HT3 receptor affinity of new quinolinecarboxylic acid derivatives.
    Orjales A; Alonso-Cires L; López-Tudanca PL; Tapia I; Labeaga L; Mosquera R
    Drug Des Discov; 2000; 16(4):271-9. PubMed ID: 10807033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel fluoro and iodo quinoline carboxamides as potential ligands of NK-3 receptors for in vivo imaging studies.
    Bennacef I; Tymciu S; Dhilly M; Lasne MC; Debruyne D; Perrio C; Barré L
    Bioorg Med Chem; 2004 Aug; 12(16):4533-41. PubMed ID: 15265501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replacement of the quinoline system in 2-phenyl-4-quinolinecarboxamide NK-3 receptor antagonists.
    Giardina GA; Artico M; Cavagnera S; Cerri A; Consolandi E; Gagliardi S; Graziani D; Grugni M; Hay DW; Luttmann MA; Mena R; Raveglia LF; Rigolio R; Sarau HM; Schmidt DB; Zanoni G; Farina C
    Farmaco; 1999 Jun; 54(6):364-74. PubMed ID: 10443017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonistic effects of FR 173657 on human, pig, rabbit, and guinea pig kinin receptors: an in vitro study.
    Rizzi A; Gobeil F; Bogoni G; Calò G; Campobasso C; Inamura N; Regoli D
    Can J Physiol Pharmacol; 1997 Jun; 75(6):601-8. PubMed ID: 9276136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
    Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lithiation of functionalized fluoroquinolines: synthesis of dihalo-2-phenylquinoline-4-carboxamides and in vitro evaluation as NK-3 receptor ligands for medical imaging studies.
    Bennacef I; Tymciu S; Dhilly M; Mongin F; Quéguiner G; Lasne MC; Barré L; Perrio C
    J Org Chem; 2004 Apr; 69(7):2622-5. PubMed ID: 15049675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New quinoline NK3 receptor antagonists with CNS activity.
    Smith PW; Wyman PA; Lovell P; Goodacre C; Serafinowska HT; Vong A; Harrington F; Flynn S; Bradley DM; Porter R; Coggon S; Murkitt G; Searle K; Thomas DR; Watson JM; Martin W; Wu Z; Dawson LA
    Bioorg Med Chem Lett; 2009 Feb; 19(3):837-40. PubMed ID: 19117759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functionalization through lithiation of (S)-N-(1-phenylpropyl)-2-phenylquinoline-4-carboxamide. Application to the labeling with carbon-11 of NK-3 receptor antagonist SB 222200.
    Bennacef I; Perrio C; Lasne MC; Barré L
    J Org Chem; 2007 Mar; 72(6):2161-5. PubMed ID: 17319724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis of new 4-heteroaryl-2-phenylquinolines and their pharmacological activity as NK-2/NK-3 receptor ligands.
    Borioni A; Mustazza C; Sestili I; Sbraccia M; Turchetto L; Del Giudice MR
    Arch Pharm (Weinheim); 2007 Jan; 340(1):17-25. PubMed ID: 17206605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization and function of NK(3) subtype tachykinin receptors of layer V pyramidal neurons of the guinea-pig medial prefrontal cortex.
    Simmons MA; Sobotka-Briner CD; Medd AM
    Neuroscience; 2008 Oct; 156(4):987-94. PubMed ID: 18801417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N(alpha)-imidazolylalkyl and pyridylalkyl derivatives of histaprodifen: synthesis and in vitro evaluation of highly potent histamine H(1)-receptor agonists.
    Menghin S; Pertz HH; Kramer K; Seifert R; Schunack W; Elz S
    J Med Chem; 2003 Dec; 46(25):5458-70. PubMed ID: 14640554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.